Rheumatology in Perspective · by Olga Goodman, MD · A RheumaView publication
Remission, Flares, and the Future
Understand what remission means, why treatment changes need a shared plan, and how to prepare for flares while continuing to make plans for the future.
Ask what the team means by remission
“The disease is quiet” is welcome news. Ask what evidence supports that conclusion and which parts of the disease have been assessed. Feeling better, having a normal blood test and meeting a formal definition of inactive disease are related, but they are not interchangeable.
Clinicians use specific definitions when describing inactive disease and remission. They also distinguish remission while taking medicine from remission after medicine has been stopped. Ask the team to explain the term in your child’s record. A medicine that is keeping inflammation controlled may still be doing an important job when symptoms are no longer noticeable.
Check the whole disease picture
Juvenile SpA can involve joints, tendon attachments and sometimes the sacroiliac joints, eyes, bowel or skin. Improvement in one part does not automatically tell the team about the others. Keep the agreed eye follow-up and report relevant new symptoms even during a good period.
Pain and fatigue can also remain when inflammation improves. They still deserve assessment and help. A symptom by itself does not prove that remission has ended, just as a reassuring blood test alone does not prove that every problem is resolved. The clinician combines the history, examination and appropriate investigations.
Understand eye, bowel and skin involvement · When pain persists despite better inflammation control
The future is a range of possibilities
Some young people have long periods of inactive disease; others experience returning or persistent inflammation and need treatment into adult life. Studies following juvenile SpA and enthesitis-related arthritis show that ongoing disease in adulthood is possible. They do not give a reliable personal forecast for a newly diagnosed child.
Older studies include people treated in earlier eras, and study groups differ in which children they include and how remission is defined. Ask what is known about your child’s particular pattern and what remains uncertain. A family history, HLA-B27 result or one scan should not be treated as a complete description of the future.
A quiet period can open a treatment discussion
Reducing treatment may become an option after sustained control, but it is a shared clinical decision. The team considers the disease pattern, previous flares, eye or bowel disease, side effects, the burden of treatment and the young person’s preferences. The best timing may also depend on whether follow-up and rapid contact are practical.
The 2026 ACR summaries conditionally favour gradual reduction rather than abrupt withdrawal of biologic treatment in relevant inactive pediatric disease. The juvenile axial SpA summary also supports considering reduced dose or frequency. These are not instructions to alter a prescription at home, and they do not establish one schedule that fits every child.
Agree the details before changing anything
Ask which medicine would change first, why that choice fits the child’s disease, and what the team would count as a successful reduction. If a medicine is treating both arthritis and eye or bowel disease, the relevant specialists should agree the plan.
Write down the authorised change, the next assessment and whom to contact if symptoms return. Clarify who will prescribe and monitor throughout. Do not stretch intervals because a prescription is running out or stop treatment to find out whether it is still needed. A supply problem needs a contact route of its own.
A possible flare needs a description
Tell the team about returning stiffness, swelling, a limp, reduced activity or a new pattern of heel, hip or back symptoms. Note when the change began, which tasks are affected and whether there are eye, bowel or skin symptoms. Mention infections, injuries, missed treatment and recent medicine changes.
A flare is one possible explanation, but infection, injury, mechanical pain and other causes can look similar. Follow the agreed contact plan rather than restarting an old medicine or increasing a dose independently. If the clinician confirms a flare after treatment reduction, the previous response helps guide the next decision.
Some changes should not wait for a flare review
A painful red eye, sensitivity to light or a change in vision needs urgent eye assessment. A child with fever and a hot swollen joint, sudden inability to bear weight, or marked illness needs urgent medical assessment. Do not assume these are routine signs of arthritis returning.
When seeking urgent care, take the current medicine list and explain that the child has inflammatory disease and may be receiving immune-modifying treatment. If the usual rheumatology contact is unavailable, use the appropriate local urgent or emergency service.
Keep making plans during good periods
School choices, friendships, travel, work interests and sport deserve attention even when the future is uncertain. Ask what support would make a particular plan feasible. It is more useful to discuss the demands of a real course, job or activity than to assume the diagnosis rules out an entire direction.
A family can keep a clear flare plan without checking for trouble all day. Choose a manageable way to record important changes and review it at agreed times. If fear of another flare is stopping ordinary life, tell the team; that worry is something they can help address.
A good period still needs a good handover
Transition to adult care should explain the original disease pattern, previous treatments, reasons for changes, important imaging and the current follow-up plan. If treatment has stopped, record when and why, and what should happen if symptoms recur. “Well at the last visit” is not a substitute for that history.
Confirm which service is responsible while care is transferred and how to obtain help between appointments. For the young person, knowing how to reconnect with care is part of independence. Remission should create space for life while preserving a route back to support if it is needed.
Prepare the move to adult care · Keep the disease story in a Transition Passport
Sources and further reading
- NIAMS: symptoms, remission and disease course in JIA
- NIAMS: ongoing care and treatment review
- ACR 2026 JIA summary: DMARD deprescribing
- ACR 2026 axial SpA summary: inactive juvenile disease, pages 22–23
- ACR: current guideline publication status
- GESPIC: four-year prospective juvenile SpA outcomes
- Nordic JIA cohort: eighteen-year outcomes
- Royal Children’s Hospital: urgent changes in a limping child
- ACR: pediatric-to-adult rheumatology transition resources